Summary of Annual Compensation
Contract Categories:
Human Resources
- Compensation Agreements
EX-10.28 2 o35253exv10w28.htm SUMMARY OF ANNUAL COMPENSATION exv10w28
Exhibit 10.28
NUCRYST PHARMACEUTICALS CORP.
DESCRIPTION OF EXECUTIVE OFFICER CASH COMPENSATION
FOR 2007
Set forth below are the 2007 annual salary of the Chief Executive Officer, the Chief Financial Officer and each of the three other most highly compensated Executive Officers.
Scott H. Gillis
President and Chief Executive Officer
President and Chief Executive Officer
| Salary | ||
| $275,000 US |
Eliot M. Lurier
Vice President, Finance and Administration and Chief Financial Officer
Vice President, Finance and Administration and Chief Financial Officer
| Salary | ||
| $171,000 US |
Paul Schechter, Ph.D., M.D.
Vice President, Drug Development & Regulatory Affairs and Chief Medical Officer
Vice President, Drug Development & Regulatory Affairs and Chief Medical Officer
| Salary | ||
| $240,000 US |
David McDowell
Vice President, Manufacturing Operations
Vice President, Manufacturing Operations
| Salary | ||
| $188,809 US1 |
Katherine J. Turner
Vice President, Research
Vice President, Research
| Salary | ||
| $195,000 US |
| 1. | Mr. McDowell’s 2007 salary has been translated into U.S. dollars for purposes of this table at the December 31, 2006 exchange rate of U.S.$1.00 = CDN $1.1652. |
In addition to salary, the named executive officers will be eligible to receive non-equity incentive compensation for 2007 corporate performance pursuant to NUCRYST’s employee variable pay program.
103
